These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36847750)

  • 1. Response of peer relations and social activities to treatment with viloxazine extended-release capsules (Qelbree
    Faraone SV; Gomeni R; Hull JT; Busse GD; Lujan B; Rubin J; Nasser A
    Brain Behav; 2023 Apr; 13(4):e2910. PubMed ID: 36847750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder.
    Faraone SV; Gomeni R; Hull JT; Busse GD; Melyan Z; Rubin J; Nasser A
    Eur Child Adolesc Psychiatry; 2023 Mar; 32(3):491-499. PubMed ID: 34581911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
    Nasser A; Hull JT; Chaturvedi SA; Liranso T; Odebo O; Kosheleff AR; Fry N; Cutler AJ; Rubin J; Schwabe S; Childress A
    CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials.
    Faraone SV; Gomeni R; Hull JT; Busse GD; Melyan Z; Rubin J; Nasser A
    Paediatr Drugs; 2021 Nov; 23(6):583-589. PubMed ID: 34523063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Nasser A; Kosheleff AR; Hull JT; Liranso T; Qin P; Busse GD; O'Neal W; Fava M; Faraone SV; Rubin J
    J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):214-226. PubMed ID: 33600233
    [No Abstract]   [Full Text] [Related]  

  • 6. A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children.
    Nasser A; Liranso T; Adewole T; Fry N; Hull JT; Chowdhry F; Busse GD; Cutler AJ; Jones NJ; Findling RL; Schwabe S
    Clin Ther; 2020 Aug; 42(8):1452-1466. PubMed ID: 32723670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controlled Trials.
    Nasser A; Hull JT; Liranso T; Busse GD; Melyan Z; Childress AC; A Lopez F; Rubin J
    Neuropsychiatr Dis Treat; 2021; 17():1751-1762. PubMed ID: 34113106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Nasser A; Liranso T; Adewole T; Fry N; Hull JT; Busse GD; Chowdhry F; Cutler AJ; Jones NJ; Findling RL; Schwabe S
    J Clin Psychopharmacol; 2021 Jul-Aug 01; 41(4):370-380. PubMed ID: 34181360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trial.
    Faraone SV; Gomeni R; Hull JT; Chaturvedi SA; Busse GD; Melyan Z; O'Neal W; Rubin J; Nasser A
    Psychiatry Res; 2022 Dec; 318():114922. PubMed ID: 36375329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial.
    Stein MA; Sikirica V; Weiss MD; Robertson B; Lyne A; Newcorn JH
    CNS Drugs; 2015 Nov; 29(11):953-62. PubMed ID: 26547425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD.
    Nasser A; Liranso T; Adewole T; Fry N; Hull JT; Chowdhry F; Busse GD; Melyan Z; Cutler AJ; Findling RL; Schwabe S
    Psychopharmacol Bull; 2021 Mar; 51(2):43-64. PubMed ID: 34092822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of placebo response in the efficacy outcome assessment in viloxazine extended-release pivotal trials in paediatric subjects with attention-deficit/hyperactivity disorder.
    Nasser A; Gomeni R; Wang Z; Hull JT; Busse GD; Melyan Z; Fava M; O'Neal W; Rubin J
    Br J Clin Pharmacol; 2022 Nov; 88(11):4828-4838. PubMed ID: 35588245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial.
    Nasser A; Liranso T; Adewole T; Fry N; Hull JT; Chowdhry F; Busse GD; Melyan Z; Cutler AJ; Findling RL; Schwabe S
    Clin Ther; 2021 Apr; 43(4):684-700. PubMed ID: 33750646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials.
    Faraone SV; Gomeni R; Hull JT; Busse GD; Melyan Z; O'Neal W; Rubin J; Nasser A
    Psychiatry Res; 2021 Feb; 296():113664. PubMed ID: 33418457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetics of Viloxazine Extended-Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder.
    Nasser A; Gomeni R; Wang Z; Kosheleff AR; Xie L; Adeojo LW; Schwabe S
    J Clin Pharmacol; 2021 Dec; 61(12):1626-1637. PubMed ID: 34269426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Wilens TE; Robertson B; Sikirica V; Harper L; Young JL; Bloomfield R; Lyne A; Rynkowski G; Cutler AJ
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):916-25.e2. PubMed ID: 26506582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder.
    Banaschewski T; Soutullo C; Lecendreux M; Johnson M; Zuddas A; Hodgkins P; Adeyi B; Squires LA; Coghill D
    CNS Drugs; 2013 Oct; 27(10):829-40. PubMed ID: 23893527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional impairment outcomes in clinical trials of different ADHD medications: post hoc responder analyses and baseline subgroup analyses.
    Coghill DR; Werner-Kiechle T; Farahbakhshian S; Bliss C; Robertson B; Huss M
    Eur Child Adolesc Psychiatry; 2021 May; 30(5):809-821. PubMed ID: 32691164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD.
    Johnson JK; Liranso T; Saylor K; Tulloch G; Adewole T; Schwabe S; Nasser A; Findling RL; Newcorn JH
    J Atten Disord; 2020 Jan; 24(2):348-358. PubMed ID: 30924702
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.